Sidley Austin is advising GlycoMimetics, Inc. on the transaction, and Gibson, Dunn & Crutcher is advising Crescent Biopharma, Inc. GlycoMimetics, Inc. (NASDAQ: GLYC) announced it has...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised Tower Arch Capital on the transaction, and Jackson Walker advised ACS Manufacturing. Tower Arch Capital announced that it has recapitalized ACS...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutcher advised Esperion Therapeutics, Inc. on the deal. Esperion Therapeutics, Inc. (Nasdaq: ESPR) announced that it has entered into a Royalty Purchase Agreement...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher represented XOMA Corporation in the transaction, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Daré. XOMA Corporation (NASDAQ: XOMA) announced...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised XOMA Corporation on the expansion of its commercial royalty and milestone portfolio with the acquisition of an economic interest in...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised Royalty Pharma in connection with its development funding. Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary...
You must be a Standard 1 Year member to access this content.
Raymond James acted as exclusive financial advisor to the Special Committee. Stifel Canada acted as independent valuator to the Special Committee. Osler, Hoskin & Harcourt LLP...
You must be a Standard 1 Year member to access this content.
